* Absolutely customisable enabling hundreds of configurations optimised for the consumer’s workflow* Helps 21 CFR half 11 and EU Annex 11 compliance with full traceability * Straightforward, seamless integration with present lab software program and LIMS Sartorius, a number one worldwide provider for the biopharmaceutical business in the present day introduced the launch of the Cubis II portfolio of balances for R&D and analytical laboratories. The balances supply best-in-class efficiency together with excessive capability, wonderful readability and sturdy stability and accuracy for all pattern sorts.Configurable {hardware} and software program are absolutely customisable to maximise operational effectivity and experimental outcomes.The Cubis II portfolio presents fashionable consumer interfaces, pharmaceutical and GxP compliance together with information dealing with, information integrity and connectivity, ergonomic pattern dealing with, simple course of integration and limitless communication on the highest stage of accuracy and precision.The balances have been designed for intuitive operation, which is additional aided by clever diagnostic methods. This ensures the next diploma of repeatability of workflows, whereas decreasing the opportunity of human error through the measurement steps. Normal working procedures may be configured as an authorised workflow.“Constructing upon the success of our Cubis line of laboratory balances, the Cubis II portfolio delivers distinctive efficiency and unmatched flexibility to satisfy the varied wants of customers in regulated environments,” stated Gerry Mackay, member of the manager board, Sartorius Lab Merchandise and Companies division. “The Cubis II integrates seamlessly into present workflows, not like common balances that will require a lab’s commonplace working procedures to be tailored to the performance of the steadiness.”Key options and advantages of the Cubis II portfolio embrace:Customised modularityA modular design and broad choice of capability and readability choices, draft defend sorts, weighing pans and shows permits 6,000 potential {hardware} configurations for optimisedworkflows. The preliminary {hardware} configuration may be enhanced over time with further equipment. New software program purposes might be accessible guaranteeing long-term flexibility and adaptation to the evolving wants of the laboratory.Highly effective, adaptable and future-proof softwareQApp software program is adaptable to particular consumer necessities. A singular on-board QApp Middle permits direct obtain of protocols and creation of customised purposes to satisfy the wants of particular person labs and customers. Clients choosing a QApp bundle will obtain all updates and new purposes for that bundle, guaranteeing a future-proof answer. Seamless connectivityCubis II balances are simply built-in with laboratory software program and LIMS methods, eliminating the necessity for separate software program islands. LIMS/information assortment software program connectivity ensures information accuracy and readiness for regulatory company submission. Assured ComplianceCubis II balances fulfil all necessities to be used in absolutely compliant processes for regulated markets equivalent to pharmaceutical and biotechnology and utilized markets includingenvironmental, meals and beverage, medical, chemical and automotive.The Cubis II is the primary steadiness to help all the necessities to realize CFR half 11 and EU annex 11 compliance in a paperless method, eliminating the opportunity of course of information or signature falsification. The balances guarantee an authenticated digital document from information acquisition to evaluation. Management over consumer entry ranges and protocols, together with the power to tug logins straight from the consumer’s LIMS system, ensures traceability and limits potential errors.About SartoriusThe Sartorius Group is a number one worldwide companion of biopharmaceutical analysis and the business. With modern laboratory devices and consumables, the Group’s Lab Merchandise & Companies Division concentrates on serving the wants of laboratories performing analysis and high quality management at pharma and biopharma firms and people of educational analysis institutes. The Bioprocess Options Division with its broad product portfolio specializing in single-use options helps clients to fabricate biotech drugs and vaccines safely and effectively. The Group has been yearly rising by double digits on common and has been often increasing its portfolio by acquisitions of complementary applied sciences. In fiscal 2018, the corporate earned gross sales income of some 1.6 billion euros. Presently, greater than 8,100 individuals work on the Group’s roughly 60 manufacturing and gross sales websites, serving clients across the globe.